Abstracts tagged "Scleroderma"

Abstract Number: 1056 • ACR Convergence 2022
Clinical Characterization of a Cohort of Patient with Sclerotic-type Chronic Graft-versus-host Disease with Fascial/joint Involvement
Cristina Hidalgo¹, Concepción Roman², Olga Compan³, Sonia Pastor Navarro⁴, Marta Ibañez⁵, Belen Miguel⁶, Maria Dolores Sanchez⁷, Lucía Pantoja⁸, Carlos Montilla⁵ and Lucía López-Corral², ¹Hospital Universitario Salamanca, Salamanca, Spain, ²Universitary Hospital, Salamanca, Spain, ³Complejo asistencial Universitario de Palencia, Carbajosa De La Sagrada, Spain, ⁴Hospital Universitario de Salamanca, Salamanca, Spain, ⁵Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ⁶University Hospital, Salamanca, Spain, ⁷Universitary Hospital, Valladolid, Spain, ⁸Complejo Asistencial Hospital General, Segovia, Spain
Background/Purpose: Graft-versus-host disease (GVHD) is the most frequent complication after allogeneic hematopoietic cell transplantation (allo-HCT). Its chronic form usually involves a multisystemic syndrome that reflects…
Abstract Number: 1190 • ACR Convergence 2022
Multimorbidity in Systemic Sclerosis: Burden and Trends in Prevalence from an Incident Population-based Cohort (1980-2018)
Ashima Makol¹, Sara Achenbach¹, Alicia Hinze², Tina Gunderson³ and Cynthia Crowson⁴, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: To estimate the prevalence and trends of multimorbidity (MM; the presence of ≥2 morbidities) in a population-based cohort of patients with Systemic sclerosis (SSc)…
Abstract Number: 1662 • ACR Convergence 2022
Nationwide Distribution of Other Connective Tissue Disease (OCTD) and Systemic Sclerosis (SSc) in Areas of Environmental Concern
Noelle Kosarek¹, Megan Romano², Robert Simms³, Angeline Andrew⁴, Erika Moen⁴, Patricia pioli⁴ and Michael Whitfield⁵, ¹Dartmouth Geisel School of Medicine, Lebanon, NH, ²Dartmouth College, Lebanon, NH, ³Dartmouth Hitchcock Medical Center, Lebanon, NH, ⁴Geisel School of Medicine at Dartmouth, Lebanon, NH, ⁵Dartmouth Geisel School of Medicine, Department of Biomedical Data Science, Lebanon, NH
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease characterized by fibrosis of the skin and internal organs, vascular abnormalities, and autoantibody formation. The etiology…
Abstract Number: 2190 • ACR Convergence 2022
Characterizing Compensatory Cognitive Strategy Use in People with Systemic Sclerosis
Yen Chen¹, Alain Lescoat², Dinesh Khanna³ and Susan Murphy⁴, ¹University of Michigan, Ann Arbor, MI, ²CHU Rennes - University Rennes 1, Rennes, France, ³Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁴University of Michigan, Grosse Ile, MI
Background/Purpose: Individuals with systemic sclerosis (SSc) report cognitive problems that worsen symptoms and daily activity performance. Compensatory cognitive strategies (CCS) are commonly taught to help…
Abstract Number: 1058 • ACR Convergence 2022
Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis
Jessica Fairley¹, Dylan Hansen², Laura Ross³, Susanna Proudman⁴, Jo Sahhar⁵, Gene-Siew Ngian⁶, Jenny Walker⁷, Lauren Host⁸, Kathleen Morrisroe², Diane Apostolopoulos⁹, Nava Ferdowsi², Michelle Wilson⁹, Maryam Tabesh², Wendy Stevens² and Mandana Nikpour¹⁰, ¹The University of Melbourne, Melbourne, Australia, ²St Vincent's Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, ⁴University of Adelaide, Medindie, Australia, ⁵Monash Health, Melbourne, Australia, ⁶Melbourne Health, Northcote, Australia, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Fiona Stanley Hospital, London, United Kingdom, ⁹Monash University, Melbourne, Australia, ¹⁰The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…
Abstract Number: 1518 • ACR Convergence 2022
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Ashima Makol¹, Alicia Hinze², Rachel Giblon¹, Yasser Radwan³, Tina Gunderson⁴, David Liedl¹, Kenneth J. Warrington⁴, Cynthia Crowson⁵ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic/ Michigan State University, Lansing, MI, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Digital ischemic complications (DICs, including digital ulcers, digital pitting/scars, gangrene and/or amputation) can significantly impact hand function, disability and overall prognosis in SSc. We…
Abstract Number: 1835 • ACR Convergence 2022
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
Magdalena Harasimowicz¹, Emily GIlbert², Sarah Yi³ and Rochella Ostrowski⁴, ¹Loyola University Medical Center Department of Internal Medicine, Chicago, IL, ²Loyola University Medical Center Division of Pulmonary and Critical Care Medicine, Maywood, IL, ³Loyola University Stritch School of Medicine, Maywood, IL, ⁴Loyola University Medical Center Division of Rheumatology, Maywood, IL
Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…
Abstract Number: 1060 • ACR Convergence 2022
Clinical Characteristics and Prognosis of Patients with Systemic Sclerosis Sine Scleroderma: Data from the International EUSTAR Database
Alain Lescoat¹, Suiyuan Huang², PATRICIA E CARREIRA³, Elise Siegert⁴, Jeska de Vries-Bouwstra⁵, Jörg Distler⁶, Vanessa Smith⁷, Branimir Anic⁸, Francesco Del Galdo⁹, Nemanja Damjanov¹⁰, Simona Rednic¹¹, camillo Ribi¹², Dominique Farge Bancel¹³, Anna-Maria Hoffmann-vold¹⁴, Armando Gabrielli¹⁵, Oliver Distler¹⁶, Dinesh Khanna¹⁷ and Yannick Allanore¹⁸, ¹CHU Rennes - University Rennes 1, Rennes, France, ²University of Michigan, Ann Arbor, MI, ³HOSPITAL 12 DE OCTUBRE, Madrid, Spain, ⁴Charité Hospital, Berlin, Germany, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁷Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium, ⁸Clinical Hospital Centre Zagreb, School of Medicine, University of Zagreb, Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, Zagreb, Croatia, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ¹⁰Institute of Rheumatology, Belgrade, Serbia, ¹¹Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania, ¹²Service of Immunology and Allergy / CHUV, Lausanne, Switzerland, ¹³Saint Louis Hospital, Paris, France, ¹⁴Oslo University Hospital, Oslo, Norway, ¹⁵Università Politecnica delle Marche, Ancona, Italy, ¹⁶Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ¹⁷Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, ¹⁸Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France
Background/Purpose: This study aimed to characterise the main clinical features of patients with systemic sclerosis (SSc) sine scleroderma (ssSSc) in comparison with the limited cutaneous…
Abstract Number: 1519 • ACR Convergence 2022
Using Galacetin-3 (Gal-3) and Cardiotrophin-1 (CT-1) for Early Detection of Primary Heart Involvement in Systemic Sclerosis as Seen on Cardiac MRI
Erin Chew¹, Sarah Wood¹, Bibin Varghese¹, Christopher Chew², erin wilfong¹ and Tracy Frech¹, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Primary heart involvement in systemic sclerosis (SSc-pHI) is characterized by myocardial inflammation with resultant fibrosis that is not secondary to ischemic heart disease or…
Abstract Number: 1946 • ACR Convergence 2022
Focused Clinical Correlation of Autoantibody Testing in Juvenile Systemic Sclerosis and Localized Scleroderma Using the Euroimmun™ Scleroderma Disease Profile
Jonathan Li¹, Emily Mirizio², Katherine Buhler³, Anne Stevens⁴, May Choi⁵, Kaila Schollaert-Fitch², Kathryn Torok², Christopher Liu² and Marvin Fritzler³, ¹Combined Internal Medicine-Pediatrics Residency Program, Children's Hospital of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Children's Hospital of UPMC, Pittsburgh, PA, ³University of Calgary, Calgary, AB, Canada, ⁴Janssen, Hansville, WA, ⁵Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada
Background/Purpose: Commercially available autoantibody (AAb) panels are developed for adult rheumatological diseases; application to pediatric disease has not been established. As a pediatric scleroderma referral…
Abstract Number: 1065 • ACR Convergence 2022
Biosamples from VEDOSS Patients Show Pathological Signs of SSc: Opportunity for a Biololgical Diagnosis of Disease
Rebecca Ross¹, Emily Clarke¹, Will Merchant¹, Panji Mulipa¹, Natalia Riobo-DelGaldo¹ and Francesco Del Galdo², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom
Background/Purpose: The VEDOSS study has recently indicated that more than 50% of patients affected by Raynaud’s phenomenon (RP) and specific SSc anti-nuclear antibodies (ANA) and/or…
Abstract Number: 1520 • ACR Convergence 2022
Rituximab and Tocilizumab and Their Effect on Lung Disease Progression in Scleroderma. a Retrospective Cohort Study at a Single Centre
Nina Goldman¹, Aoife Tynan², Shivani Shah², Claire Beesley¹, Rizgar Mageed³, Chris Denton¹ and Voon Ong⁴, ¹University College London, London, United Kingdom, ²Division of Medicine, Department of Rheumatology, University College London, London, United Kingdom, ³Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, ⁴UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose: Interstitial lung disease (ILD) is one of the leading causes of mortality in systemic sclerosis (SSc). Emerging evidence suggests a beneficial effect of tocilizumab…
Abstract Number: 2036 • ACR Convergence 2022
Development of Systemic Sclerosis in Patients with Primary Sjogren Syndrome and Raynauds Phenomenon
Andres Martinez¹, Julieta Morbiducci¹, Constanza Arguissain¹, Maria Tamborenea¹, Marisel Bejarano², Lucia Castorino¹ and Anastasia Secco¹, ¹Rivadavia Hospital, Buenos Aires, Argentina, ²Rivadavia´s Hospital, Buenos Aires, Argentina
Background/Purpose: Primary Sjögren's Syndrome (pSS) is an autoimmune disease, and Raynaud's Phenomenon (RP) is an extraglandular manifestation that can evolve into a systemic sclerosis-overlap syndrome.…
Abstract Number: 0003 • ACR Convergence 2022
Rituximab versus Cyclophosphamide for the Treatment of Connective Tissue Disease Associated Interstitial Lung Disease (RECITAL): A Sub-group Analysis of a Multi-centre Randomised Controlled Trial
Toby Maher¹, Veronica Tudor², Peter Saunders³, Michael Gibbons⁴, Sophie Fletcher⁵, Helen Parfrey⁶, Chris Denton⁷, Rachel Hoyles³, Elizabeth Renzoni², Maria Kokosi², Athol Wells², Deborah Ashby⁸, Matyas Szigeti⁸ and Philip Molyneaux⁸, ¹University of Southern California, Los Angeles, CA, ²Royal Brompton Hospital, London, United Kingdom, ³Oxford University Hospitals, Oxford, United Kingdom, ⁴Royal Devon and Exeter Hospital, Exeter, United Kingdom, ⁵Southampton University Hospitals, Southampton, United Kingdom, ⁶Addenbrookes Hospital, Cambridge, United Kingdom, ⁷University College London, London, United Kingdom, ⁸Imperial College London, London, United Kingdom
Background/Purpose: The RECITAL trial (NCT01862926) compared rituximab to cyclophosphamide as first line therapy for patients with severe or progressive interstitial lung disease due to idiopathic…
Abstract Number: 1068 • ACR Convergence 2022
Anti-vinculin Antibodies in Systemic Sclerosis: Associations with Slow Gastric Transit and Extra-Intestinal Clinical Phenotype
Maria Herran¹, Brit Adler², Jamie Perin³, Walter Morales⁴, Mark Pimentel⁵ and Zsuzsanna McMahan⁶, ¹School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia, ²Johns Hopkins University, Division of Rheumatology, Baltimore, MD, ³John Hopkins University, Baltimore, MD, ⁴Medically Associated Science and Technology (MAST) Program, Cedars-Sinai, Los Angeles, CA, ⁵Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai, Los Angeles, CA, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: The gastrointestinal tract is commonly affected in systemic sclerosis (SSc). Prior studies have reported an association between higher levels of anti-vinculin antibodies and gastrointestinal…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].